Drug intelligence / Profile preview

RG6540

Development stage: Unknown
Lead developer: Roche
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RG6540 is an investigational bispecific monoclonal antibody developed by Genentech (a member of the Roche Group) for the treatment of hematologic malignancies. It is designed to simultaneously target two distinct B-cell surface antigens, CD19 and CD20. By engaging both targets on malignant B cells, RG6540 aims to enhance anti-tumor activity and potentially overcome resistance mechanisms associated with single-antigen targeting, such as antigen escape. The drug is currently in Phase I clinical development, representing a biologic therapeutic approach to treating various heme tumors.

Targets

CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on RG6540.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG6540.

Explore the full profile